Skip to main content
SpringerLink
Log in

The effect of cigarette smoke on gastroduodenal mucosal endogenous prostacyclin level (Experimental and clinical observations)

  • Immunosuppression and Inflammation
  • Published:
Agents and Actions Aims and scope Submit manuscript

Abstract

In our opinion the endogenous prostacyclin (PGI2) is one of the most important natural protective substances in the gastric mucosa. We have, therefore checked in experimental circumstances in rats, as well as in clinical observations in humans, the possible effect of smoking on endogenous gastroduodenal mucosal PGI2 level.

The animal experiments seem to verify that cigarette smoke really has an unwanted effect on the gastric mucosa. The target of this action is the endogenous PGI2 content of the mucosa.

According to our observations in humans there is a definite tendency toward decreased endogenous PGI2 production in the gastroduodenal mucosa of smokers too.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. J. R. Vane,Inhibition of prostaglandin synthetase as a mechanism of action for aspirin-like drugs. Nature (Lond)231, 232–235 (1961).

    Google Scholar 

  2. G. A. Higgs, E. A. Harvey, S. H. Ferreira and J. R. Vane,The effect of anti-inflammatory drugs on the production of prostaglandin in vivo. In:Advances in prostaglandin and thromboxane research. pp. 105–110 (Eds. B. Samuelsson and R. Poaletti). Raven-Press, New York 1976.

    Google Scholar 

  3. D. A. Brodie and B. J. Chase,Role of gastric acid in aspirin-induced gastric irritation in the rat. Gastroenterology53, 604–610 (1967).

    PubMed  Google Scholar 

  4. R. Bugat, M. R. Thompson, D. Aures and M. I. Grossman,Gastric mucosal lesions produced by intravenous infusion of aspirin in rats. Gastroenterology71, 754–759 (1976).

    PubMed  Google Scholar 

  5. A. Levy,Aspirin use in patients with major upper gastrointestinal bleeding and peptic-ulcer disease. N. Engl. J. Med.290, 1158–1162 (1974).

    PubMed  Google Scholar 

  6. M. I. Grossman, K. K. Matsumoto and R. J. Lichter,Fecal blood loss produced by oral and intravenous administration of various salicylates. Gastroenterology40, 383–388 (1961).

    PubMed  Google Scholar 

  7. T. A. Miller and E. D. Jacobson,Gastrointestinal cytoprotection by prostaglandins. Gut20, 75–87 (1979).

    PubMed  Google Scholar 

  8. R. R. Martel, J. Klicius and F. Herr,Investigation of 1,3,4,9-tetrahydro-1-propylpyrano-[3,4-b]-indole-1-acetic acid [Prodolic acid]. A new nonsteroidal anti-inflammatory agent in rats. Agents and Actions4, 370–376 (1974).

    PubMed  Google Scholar 

  9. C. A. Demerson, L. G. Humber, A. H. Philipp and R. R. Martel,Etodolic acid and related compounds. Chemistry and anti-inflammatory actions of some potent di-and tri-substituted 1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acids. J. Med. Chem.19, 391–395 (1976).

    PubMed  Google Scholar 

  10. R. R. Martel and J. Klicius,Anti-inflammatory and analgesic properties of etodolic acid in rats. Can. J. Physiol. Pharmacol.54, 245–248 (1976).

    PubMed  Google Scholar 

  11. R. R. Martel and J. Klicius,Comparison in rats of the anti-inflammatory and gastric irritant effects of etodolac with several clinically effective anti-inflammatory drugs. Agents and Actions12, 295–297 (1982).

    PubMed  Google Scholar 

  12. J. Joubert, J. F. Mullane and M. Merlo et al.,Clinical pharmacological profile of Ultradol, a new nonsteroidal anti-inflammatory drug. Curr. Ther. Res.32, 74–88 (1982).

    Google Scholar 

  13. G. Vetter, M. Placchi and L. Jourbert,Comparative efficacy of etodolac and placebo in rheumatoid arthritic patients. Intl. J. Clin. Pharmacol. Ther. Toxicol.10, 240–245 (1982).

    Google Scholar 

  14. S. Ryder, J. Salmon, G. Jacob, M. Sanda, and J. Huth,Etodolac (Ultradol)—the safety profile of a new structurally novel nonsteroidal anti-inflammatory drug. Curr. Ther. Res.33, 948–965 (1983).

    Google Scholar 

  15. J. D. Arnold, J. Mullane and D. Hayden et al.,Etodolac, aspirin, and gastro-intestinal microbleeding. Clin. Pharmacol. Ther.35, 716–721 (1984).

    PubMed  Google Scholar 

  16. I. Salom, G. Jacob, N. Jallad, C. A. Perdomo, J. F. Mullane and D. Weidler,Gastrointestinal microbleeding associated with the use of etodolac, ibuprofen, indomethacin, and naproxen in normal subjects. J. Clin. Pharmacol.24, 240–246 (1983).

    Google Scholar 

  17. M. Sanda, S. H. Collins, J. Mahady, J. Huth and K. Krantz,Three-month multicenter study of etodolac (Ultradol ®)in patients with osteorthritis of the hip. Curr. Ther. Res.33, 782–792 (1984).

    Google Scholar 

  18. G. B. Jacob, K. K. Hart, J. F. Mullane, S. Lutins and T. Y. Lee,Placebo-controlled study of etodolac and aspirin in the treatment of rheumatoid arthritis. Curr. Ther. Res.33, 703–713 (1983).

    Google Scholar 

  19. G. Jacob, M. Messina, E. Caperton, R. Gordon, G. Harris, B. Sack, P. Vreede and R. Weitzman,Safety and efficacy of etodolac, once or twice a day in the treatment of active rheumatoid arthritis. Curr. Ther. Res.37, 1124–1129 (1985).

    Google Scholar 

  20. E. S. Ferdinandi, M. N. Cayen and C. Pace-Asciak,Disposition of etodolac, other anti-inflammatory pyranoidole-1-acetic acids and furobufen in normal and adjuvant arthritic rats. J Pharmacol. Exp. Therap.220, 417–426 (1982).

    Google Scholar 

  21. D. Lee and D. Dvornik,Etodolac: effect on prostaglandin concentrations in gastric mucosa of rats. Life Sci36, 1157–1162 (1985).

    PubMed  Google Scholar 

  22. M. N. Cayen, M. Kraml, E. S. Ferdinandi, E. Greselin and D. Dvornik,The metabolic disposition of etodolac in rats, dogs, and man. Drug Metab. Rev.12, 339–362 (1981).

    PubMed  Google Scholar 

  23. R. R. Martel, J. Klicius and G. Metcalf,Effect of etodolac on articular and bone pathology associated with adjuvant arthritis in rats: a comparison with aspirin and naproxen. Agents and Actions14, 257–264 (1984).

    PubMed  Google Scholar 

  24. R. Runkel, M. Chaplin, G. Boost, E. Segra and E. Forchielli,Absorption, distribution, metabolism, and excretion of naproxen in various laboratory animals and human subjects. J. Pharma. Sci.61, 703–708 (1972).

    Google Scholar 

  25. S. K. Baker and S. Niazi,Effect of water deprivation on aspirin disposition kinetics. J. Pharm. Sci.72, 1030–1034 (1983).

    PubMed  Google Scholar 

  26. W. S. Powell,Rapid extraction of arachidonic acid metabolites from biological samples using octadecylsilyl silica. Methods in Enzymology86, 467–477 (1982).

    PubMed  Google Scholar 

  27. F. A. Kuehl and R. W. Egan,Prostaglandins, arachidonic acid, and inflammation. Science210, 978–984 (1980).

    PubMed  Google Scholar 

  28. D. Lee,Effect of etodolac (E) on the gastric mucosal prostaglandin levels in the rat. Fed. Proc.44, 1840 (1985).

    Google Scholar 

  29. M. Ligumsky, E. M. Golanska, D. G. Hansen and G. L. Kauffman Jr,Aspirin can inhibit gastric mucosal cyclooxygenase without causing lesions in rats. Gastroenterology84, 756–761 (1983).

    PubMed  Google Scholar 

  30. S. J. Konturek, I. Piastucki and T. Brzozowski et al.,Role of prostaglandins in the formation of aspirin-induced gastric ulcers. Gastroenterology80, 4–9 (1981).

    PubMed  Google Scholar 

  31. B. J. R. Whittle, N. K. Blughton-Smith, S. Moncada and J. R. Vane,Actions of prostacyclin (PGI 2)and its product, 6-oxo-PFG 1α on the rat gastric mucosa in vivo and in vitro. Prostaglandins15, 955–967 (1978).

    PubMed  Google Scholar 

  32. M. Kraml, L. Cosyns and D. R. Hicks et al.,Bioavailability studies with etodolac in dogs and man. Biopharmaceutics Drug Disp.5, 63–74 (1985).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. First Department of Medicine, University Medical School, P.O. Box 469, H-6701, Szeged, Hungary

    G. A. Balint & V. Varró

Authors
  1. G. A. Balint
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V. Varró
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Balint, G.A., Varró, V. The effect of cigarette smoke on gastroduodenal mucosal endogenous prostacyclin level (Experimental and clinical observations). Agents and Actions 19, 224–232 (1986). https://doi.org/10.1007/BF01966210

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01966210

Keywords

Search

Navigation